Redwood City, California, United States, November 2025 — Kevin Norrett has assumed a significant leadership role as the Chief Business Officer at Soleno Therapeutics, Inc. In this executive position reporting directly to the CEO, he will oversee corporate strategy, business development, strategic partnerships, portfolio prioritization, program management, and corporate governance while serving as a key executive interface with investors, analysts, and global stakeholders.
Prior to joining Soleno Therapeutics, Kevin served as Chief Operating Officer at Codexis, Inc. where he contributed approximately three years toward shaping corporate strategy, operational excellence, business development, and commercial growth. His responsibilities extended across sales and marketing, strategic communications, and organizational leadership as the company advanced its innovation roadmap.
Before Codexis, he served as Chief Business and Commercial Officer at Sierra Oncology, where he drove business development, commercial strategy, organizational planning, and corporate communications. His contributions helped strengthen commercialization readiness and enterprise alignment during a strategic phase of the company’s evolution.
Earlier, Kevin served as Chief Commercial Officer at Angion, leading commercial operations, business development strategy, and external communications. Prior to that, he spent more than two years with Aimmune Therapeutics, progressing through multiple strategic leadership roles including VP, Global Market Access & Customer Solutions; VP, Global Market Access & US Commercial Operations; and VP, Marketing, Market Access & Commercial Operations, where he oversaw U.S. commercialization efforts, market access, and large-scale launch coordination with physician, payer, and consumer ecosystems.
Kevin’s earlier career includes impactful tenures with ZS Pharma, Inc.; Exelixis Inc.; Genentech; Cowen & Company; SyStemix, Inc., where he built a deep foundation spanning market access, oncology commercialization, pricing and reimbursement strategy, portfolio forecasting, corporate finance, investment banking, and development of high-value pharmaceutical and biotech commercialization pathways across the U.S. healthcare ecosystem.
About Soleno Therapeutics, Inc.
Soleno Therapeutics, Inc. is a biopharmaceutical organization driven by science, advocacy, and purpose. With a strong commitment to serving the Prader-Willi syndrome (PWS) community and rare disease ecosystems, Soleno develops transformative therapies that change lives.
In March 2025, Soleno’s therapy for the treatment of hyperphagia in Prader-Willi syndrome became the first and only FDA-approved treatment for the condition — marking a landmark step forward for rare disease care, patient dignity, and global healthcare progress. The company continues advancing innovation with an unwavering focus on clinical rigor, patient impact, and meaningful partnership with caregivers, clinicians, and the rare disease community.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work










